Chamberlain University
NR 546 / NR546
Week 3 Antipsychotics Table
Course: Advanced Pharmacology
- / 2
Drug name Indicaon
Target symptoms: state if posive or negave
eect Potency (if noted. receptor occupancy if noted ) Neurotransmier(s) aected Half-life (T1/2), metabolism (CYP 450 enzyme) Notable side eects (associate to pathway or NT) Typical anpsychocs (convenonal)
Haloperidol Target Symptoms:
Bipolar Disorder Psychoc disorders Behavioral disturbances in demenas Delirium w/ Lorazepam Schizophrenia Tics and vocal uerances in Tourees Syndrome Second line treatment of severe behavior in children of combave explosive hyperexcitability
Potency:
High potency rst-generaon
Neurotransmiers:
Blocks dopamine 2 receptors, reducing posive symptoms of psychosis and possibly combave, explosive, and hyperacve behaviors Blocks dopamine 2 receptors in the nigrostriatal pathway, improving cs and other symptoms in Touree’s syndrome.
Half-Life:
Decanoate is approx.
- weeks
Oral: 12-38 hours
Metabolism:
CYP1A2
CYP2D6
CYP3A4
Notable Side Eects:
Neurolepc-induced decit syndrome Akathisia Drug-induced Parkinsonism Tardive dyskinesia, Tardive dystonia Risk of potenally irreversible involuntary dyskinec movements may increase with cumulave dose and treatment duraon Galactorrhea, Amenorrhea Dizziness Sedaon Dry mouth, conspaon, urinary retenon, blurred vision Decreased sweang Hypotension Tachycardia Hypertension Weight gain
Thioridazine Target Symptoms:
Schizophrenia
Potency:
Low-potency rst-generaon
Neurotransmiers:
Blocks dopamine 2 receptors, reducing posive symptoms of psychosis
Half-Life:
21-24 Hours
Metabolism:
CYP450 2D6
Notable Side Eects:
Neurolepc-induced decit syndrome Akathisia Priapism Drug- induced parkinsonism Tardive dyskinesia Risk of potenally irreversible involuntary dyskinec movements may increase with cumulave dose Downloaded by Benjamin Luca ([email protected]) lOMoARcPSD|51648332
- / 2